The genetic landscape of Alzheimer disease: clinical implications and perspectives
C Van Cauwenberghe, C Van Broeckhoven… - Genetics in …, 2016 - nature.com
The search for the genetic factors contributing to Alzheimer disease (AD) has evolved
tremendously throughout the years. It started from the discovery of fully penetrant mutations …
tremendously throughout the years. It started from the discovery of fully penetrant mutations …
Age, APOE and sex: triad of risk of Alzheimer's disease
Age, apolipoprotein E ε4 (APOE) and chromosomal sex are well-established risk factors for
late-onset Alzheimer's disease (LOAD; AD). Over 60% of persons with AD harbor at least …
late-onset Alzheimer's disease (LOAD; AD). Over 60% of persons with AD harbor at least …
Mitochondrial dysfunction: the missing link between aging and sporadic Alzheimer's disease
Alzheimer's disease (AD) is a progressive neurodegenerative disease that represents the
most common form of dementia among the elderly. Despite the fact that AD was studied for …
most common form of dementia among the elderly. Despite the fact that AD was studied for …
Altered energy metabolism pathways in the posterior cingulate in young adult apolipoprotein E ɛ4 carriers
M Perkins, AB Wolf, B Chavira… - Journal of …, 2016 - content.iospress.com
The APOE gene, encoding apolipoprotein E, is the primary genetic risk factor for late-onset
Alzheimer's disease (AD). Apolipoprotein E ɛ4 allele (APOE4) carriers have alterations in …
Alzheimer's disease (AD). Apolipoprotein E ɛ4 allele (APOE4) carriers have alterations in …
[HTML][HTML] Understanding the genetics of APOE and TOMM40 and role of mitochondrial structure and function in clinical pharmacology of Alzheimer's disease
A Roses, S Sundseth, A Saunders, W Gottschalk… - Alzheimer's & …, 2016 - Elsevier
Abstract The methodology of Genome-Wide Association Screening (GWAS) has been
applied for more than a decade. Translation to clinical utility has been limited, especially in …
applied for more than a decade. Translation to clinical utility has been limited, especially in …
Pharmacogenetic considerations in the treatment of Alzheimer's disease
R Cacabelos, C Torrellas, O Teijido… - Pharmacogenomics, 2016 - Taylor & Francis
The practical pharmacogenetics of Alzheimer's disease (AD) is circumscribed to
acetylcholinesterase inhibitors (AChEIs) and memantine. However, pharmacogenetic …
acetylcholinesterase inhibitors (AChEIs) and memantine. However, pharmacogenetic …
A TOMM40 poly-T variant modulates gene expression and is associated with vocabulary ability and decline in nonpathologic aging
Abstract The Translocase of Outer Mitochondrial Membrane 40 Homolog and Apolipoprotein
E (TOMM40-APOE) locus has been associated with a number of age-related phenotypes in …
E (TOMM40-APOE) locus has been associated with a number of age-related phenotypes in …
Blood glucose levels and cortical thinning in cognitively normal, middle-aged adults
AMV Wennberg, AP Spira, C Pettigrew… - Journal of the …, 2016 - Elsevier
Type II diabetes mellitus (DM) increases risk for cognitive decline and is associated with
brain atrophy in older demented and non-demented individuals. We investigated (1) the …
brain atrophy in older demented and non-demented individuals. We investigated (1) the …
The enemy within: innate surveillance-mediated cell death, the common mechanism of neurodegenerative disease
RI Richards, SA Robertson, LV O'Keefe… - Frontiers in …, 2016 - frontiersin.org
Neurodegenerative diseases comprise an array of progressive neurological disorders all
characterized by the selective death of neurons in the central nervous system. Although, rare …
characterized by the selective death of neurons in the central nervous system. Although, rare …
New Genetic Approaches to AD: Lessons from APOE-TOMM40 Phylogenetics
MW Lutz, D Crenshaw, KA Welsh-Bohmer… - Current Neurology and …, 2016 - Springer
Clinical trials for Alzheimer's disease are now focusing on the earliest stages of the disease
with the goal of delaying dementia onset. There is great utility in using genetic variants to …
with the goal of delaying dementia onset. There is great utility in using genetic variants to …